During the past decade, Sir Mortimer B. Davis Jewish General Hospital conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 25 clinical trials were completed, i.e. on average, 92.6% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 12 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sir Mortimer B. Davis Jewish General Hospital" #1 sponsor was "Pfizer" with 8 trials, followed by "Bayer" with 6 trials sponsored, "Sir Mortimer B. Davis - Jewish General Hospital" with 6 trials sponsored, "Celgene" with 5 trials sponsored and "Ottawa Hospital Research Institute" with 5 trials sponsored. Other sponsors include 40 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sir Mortimer B. Davis Jewish General Hospital" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 6 trials as a collaborator, "Sigvaris Corporation" with 3 trials as a collaborator, "Heart and Stroke Foundation of Canada" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "Sir Mortimer B. Davis - Jewish General Hospital" with 2 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Sir Mortimer B. Davis Jewish General Hospital" are "Pulmonary Arterial Hypertension" (5 trials), "Multiple Myeloma" (4 trials), "Myelodysplastic Syndromes" (4 trials), "Venous Thromboembolism" (4 trials) and "Colorectal Cancer" (3 trials). Many other conditions were trialed in "Sir Mortimer B. Davis Jewish General Hospital" in a lesser frequency.

Most popular intervention types in "Sir Mortimer B. Davis Jewish General Hospital" are "Drug" (57 trials), "Biological" (5 trials), "Device" (5 trials), "Other" (4 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "MGCD0103" (4 trials), "Dexamethasone" (3 trials), "Carfilzomib" (2 trials) and "Cetuximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Sir Mortimer B. Davis Jewish General Hospital" are 70 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Sir Mortimer B. Davis Jewish General Hospital". 1 are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 48 completed trials in Sir Mortimer B. Davis Jewish General Hospital, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Sir Mortimer B. Davis Jewish General Hospital, 15 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".